-
1
-
-
0015458302
-
Inhibitory effect of L-dopa on GH release in acromegalic patients
-
A. Liuzzi, P.G. Chiodini, L. Botalla, G. Cremascoli, F. Silvestrini, Inhibitory effect of L-dopa on GH release in acromegalic patients. J. Clin. Endocrinol. Metab. 35, 941-943 (1972)
-
(1972)
J. Clin. Endocrinol. Metab.
, vol.35
, pp. 941-943
-
-
Liuzzi, A.1
Chiodini, P.G.2
Botalla, L.3
Cremascoli, G.4
Silvestrini, F.5
-
2
-
-
84995823862
-
The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects
-
R.B. Mims, R.B. Stein, J.E. Bethune, The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects. J. Clin. Endocrinol. Metab. 37, 34-39 (1973)
-
(1973)
J. Clin. Endocrinol. Metab.
, vol.37
, pp. 34-39
-
-
Mims, R.B.1
Stein, R.B.2
Bethune, J.E.3
-
3
-
-
0016434731
-
Bromocriptine treatment of acromegaly
-
M.O. Thorner, A. Chait, M. Aitken, G. Benker, S.R. Bloom, C.H. Mortimer, P. Sanders, A.S. Mason, G.M. Besser, Bromocriptine treatment of acromegaly. Br. Med. J. 1, 299-303 (1975)
-
(1975)
Br. Med. J.
, vol.1
, pp. 299-303
-
-
Thorner, M.O.1
Chait, A.2
Aitken, M.3
Benker, G.4
Bloom, S.R.5
Mortimer, C.H.6
Sanders, P.7
Mason, A.S.8
Besser, G.M.9
-
4
-
-
0017365170
-
Long-term treatment of acromegaly with bromocriptine
-
J.A. Wass, M.O. Thorner, D.V. Morris, L.H. Rees, A.S. Mason, A.E. Jones, G.M. Besser, Long-term treatment of acromegaly with bromocriptine. Br. Med. J. 1, 875-878 (1977)
-
(1977)
Br. Med. J.
, vol.1
, pp. 875-878
-
-
Wass, J.A.1
Thorner, M.O.2
Morris, D.V.3
Rees, L.H.4
Mason, A.S.5
Jones, A.E.6
Besser, G.M.7
-
5
-
-
33845491265
-
Medical progress: Acromegaly
-
S. Melmed, Medical progress: acromegaly. N. Engl. J. Med. 14(355), 2558-2573 (2006)
-
(2006)
N. Engl. J. Med.
, vol.14
, Issue.355
, pp. 2558-2573
-
-
Melmed, S.1
-
6
-
-
0028146981
-
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
-
Cabergoline comparative study group
-
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N. Engl. J. Med. 331, 904-909 (1994)
-
(1994)
N. Engl. J. Med.
, vol.331
, pp. 904-909
-
-
Webster, J.1
Piscitelli, G.2
Polli, A.3
Ferrari, C.I.4
Ismail, I.5
Scanlon, M.F.6
-
7
-
-
77952124423
-
Prolactinomas, Cushing's disease and acromegaly: Debating the role of medical therapy for secretory pituitary adenomas
-
B.M. Biller, A. Colao, S. Petersenn, V.S. Bonert, M. Boscaro, Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr. Disord. 10, 10 (2010)
-
(2010)
BMC Endocr. Disord.
, vol.10
, pp. 10
-
-
Biller, B.M.1
Colao, A.2
Petersenn, S.3
Bonert, V.S.4
Boscaro, M.5
-
8
-
-
0041430890
-
Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells
-
J.J. An, S.R. Cho, D.W. Jeong, K.W. Park, Y.S. Ahn, J.H. Baik, Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol. Cell. Endocrinol. 206, 49-62 (2003)
-
(2003)
Mol. Cell. Endocrinol.
, vol.206
, pp. 49-62
-
-
An, J.J.1
Cho, S.R.2
Jeong, D.W.3
Park, K.W.4
Ahn, Y.S.5
Baik, J.H.6
-
9
-
-
0022509629
-
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
-
C. Ferrari, C. Barbieri, R. Caldara, M. Mucci, F. Codecasa, A. Paracchi, C. Romano, M. Boghen, A. Dubini, Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63, 941-945 (1986)
-
(1986)
J. Clin. Endocrinol. Metab.
, vol.63
, pp. 941-945
-
-
Ferrari, C.1
Barbieri, C.2
Caldara, R.3
Mucci, M.4
Codecasa, F.5
Paracchi, A.6
Romano, C.7
Boghen, M.8
Dubini, A.9
-
10
-
-
0023775877
-
Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients
-
Oxf.
-
C. Ferrari, A. Paracchi, C. Romano, G. Gerevini, M. Boghen, A. Barreca, P. Fortini, A. Dubini, Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 29, 467-476 (1988)
-
(1988)
Clin. Endocrinol.
, vol.29
, pp. 467-476
-
-
Ferrari, C.1
Paracchi, A.2
Romano, C.3
Gerevini, G.4
Boghen, M.5
Barreca, A.6
Fortini, P.7
Dubini, A.8
-
11
-
-
0031026529
-
Effect of different dopaminergic agents in the treatment of acromegaly
-
A. Colao, D. Ferone, P. Marzullo, A. Di Sarno, G. Cerbone, F. Sarnacchiaro, S. Cirillo, B. Merola, G. Lombardi, Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82, 518-523 (1997)
-
(1997)
J. Clin. Endocrinol. Metab.
, vol.82
, pp. 518-523
-
-
Colao, A.1
Ferone, D.2
Marzullo, P.3
Di Sarno, A.4
Cerbone, G.5
Sarnacchiaro, F.6
Cirillo, S.7
Merola, B.8
Lombardi, G.9
-
12
-
-
0030740018
-
Cabergoline treatment of acromegaly: A preliminary dose finding study
-
Oxf.
-
S.N. Jackson, J. Fowler, T.A. Howlett, Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 46, 745-749 (1997)
-
(1997)
Clin. Endocrinol.
, vol.46
, pp. 745-749
-
-
Jackson, S.N.1
Fowler, J.2
Howlett, T.A.3
-
13
-
-
0031767931
-
Cabergoline in acromegaly: A renewed role for dopamine agonist treatment?
-
R. Cozzi, R. Attanasio, M. Barausse, D. Dallabonzana, P. Orlandi, N. Da Re, V. Branca, G. Oppizzi, D. Gelli, Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur. J. Endocrinol. 139, 516-521 (1998)
-
(1998)
Eur. J. Endocrinol.
, vol.139
, pp. 516-521
-
-
Cozzi, R.1
Attanasio, R.2
Barausse, M.3
Dallabonzana, D.4
Orlandi, P.5
Da Re, N.6
Branca, V.7
Oppizzi, G.8
Gelli, D.9
-
14
-
-
0031792509
-
Cabergoline in the treatment of acromegaly: A study in 64 patients
-
R. Abs, J. Verhelst, D. Maiter, K. Van Acker, F. Nobels, J.L. Coolens, C. Mahler, A. Beckers, Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83, 374-378 (1998)
-
(1998)
J. Clin. Endocrinol. Metab.
, vol.83
, pp. 374-378
-
-
Abs, R.1
Verhelst, J.2
Maiter, D.3
Van Acker, K.4
Nobels, F.5
Coolens, J.L.6
Mahler, C.7
Beckers, A.8
-
15
-
-
34548462041
-
Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy
-
L. Vilar, M.A. Czepielewsk, L.A. Naves, G.A. Rollin, L.A. Casulari, C.E. Coelho, Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr. Pract. 13, 396-402 (2007)
-
(2007)
Endocr. Pract.
, vol.13
, pp. 396-402
-
-
Vilar, L.1
Czepielewsk, M.A.2
Naves, L.A.3
Rollin, G.A.4
Casulari, L.A.5
Coelho, C.E.6
-
16
-
-
56749098338
-
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
-
V.J. Moyes, K.A. Metcalfe, W.M. Drake, Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur. J. Endocrinol. 159, 541-545 (2008)
-
(2008)
Eur. J. Endocrinol.
, vol.159
, pp. 541-545
-
-
Moyes, V.J.1
Metcalfe, K.A.2
Drake, W.M.3
-
17
-
-
5544284786
-
Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors
-
P.U. Freda, C.M. Reyes, A.T. Nuruzzaman, R.E. Sundeen, A.G. Khandji, K.D. Post, Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7, 21-30 (2004)
-
(2004)
Pituitary
, vol.7
, pp. 21-30
-
-
Freda, P.U.1
Reyes, C.M.2
Nuruzzaman, A.T.3
Sundeen, R.E.4
Khandji, A.G.5
Post, K.D.6
-
19
-
-
14944339645
-
Cabergoline decreases somatotroph adenoma size: A case report
-
M.R. Rickels, P.J. Snyder, Cabergoline decreases somatotroph adenoma size: a case report. Pituitary 7, 107-110 (2004)
-
(2004)
Pituitary
, vol.7
, pp. 107-110
-
-
Rickels, M.R.1
Snyder, P.J.2
-
20
-
-
38649113922
-
Remission of acromegaly following long-term therapy with cabergoline: Report of two cases
-
J.A. Verhelst, P.J. Abrams, R. Abs, Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11, 103-107 (2008)
-
(2008)
Pituitary
, vol.11
, pp. 103-107
-
-
Verhelst, J.A.1
Abrams, P.J.2
Abs, R.3
-
21
-
-
0033288398
-
Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients
-
P. Marzullo, D. Ferone, C. Di Somma, R. Pivonello, M. Filippella, G. Lombardi, A. Colao, Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1, 115-120 (1999)
-
(1999)
Pituitary
, vol.1
, pp. 115-120
-
-
Marzullo, P.1
Ferone, D.2
Di Somma, C.3
Pivonello, R.4
Filippella, M.5
Lombardi, G.6
Colao, A.7
-
22
-
-
4143066821
-
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status
-
Oxf.
-
R. Cozzi, R. Attanasio, S. Lodrini, G. Lasio, Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.) 61, 209-215 (2004)
-
(2004)
Clin. Endocrinol.
, vol.61
, pp. 209-215
-
-
Cozzi, R.1
Attanasio, R.2
Lodrini, S.3
Lasio, G.4
-
23
-
-
26644444556
-
Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients
-
Oxf.
-
B. Gatta, D.H. Hau, B. Catargi, P. Roger, A. Tabarin, Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. (Oxf.) 63, 477-478 (2005)
-
(2005)
Clin. Endocrinol.
, vol.63
, pp. 477-478
-
-
Gatta, B.1
Hau, D.H.2
Catargi, B.3
Roger, P.4
Tabarin, A.5
-
24
-
-
17744392005
-
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
-
D. Selvarajah, J. Webster, R. Ross, J. Newell-Price, Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152, 569-574 (2005)
-
(2005)
Eur. J. Endocrinol.
, vol.152
, pp. 569-574
-
-
Selvarajah, D.1
Webster, J.2
Ross, R.3
Newell-Price, J.4
-
25
-
-
67651108793
-
Optimizing medical therapy of acromegaly: Beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide
-
R.S. Jallad, M.D. Bronstein, Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90, 82-92 (2009)
-
(2009)
Neuroendocrinology
, vol.90
, pp. 82-92
-
-
Jallad, R.S.1
Bronstein, M.D.2
-
26
-
-
84902354135
-
Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly
-
on behalf of the ACROCOMB study group
-
Vilchez R, Bernabeu I, Blanco C, Cordido F, Paja M, Casany R, Fajardo C, Maraver S, Martín T, Lucas T, García Arnes JA, Fernández Catalina P, Martínez de Icaya MP, Sesmilo G, Picó A, Marazuela M, Soto A, Puig Domingo M, on behalf of the ACROCOMB study group. Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly. The Endocrine Society's 95th Annual Meeting & Expo 15-18 June 2013, San Francisco, CA, USA
-
The Endocrine Society's 95th Annual Meeting & Expo 15-18 June 2013, San Francisco, CA, USA
-
-
Vilchez, R.1
Bernabeu, I.2
Blanco, C.3
Cordido, F.4
Paja, M.5
Casany, R.6
Fajardo, C.7
Maraver, S.8
Martín, T.9
Lucas, T.10
García Arnes, J.A.11
Fernández Catalina, P.12
Martínez De Icaya, M.P.13
Sesmilo, G.14
Picó, A.15
Marazuela, M.16
Soto, A.17
Puig Domingo, M.18
-
27
-
-
79955577752
-
Resistance to somatostatin analogs in acromegaly
-
A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32, 247-271 (2011)
-
(2011)
Endocr. Rev.
, vol.32
, pp. 247-271
-
-
Colao, A.1
Auriemma, R.S.2
Lombardi, G.3
Pivonello, R.4
-
28
-
-
65249099703
-
Medical therapy in patients with acromegaly: Predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues
-
M. Sherlock, E. Fernandez-Rodriguez, A.A. Alonso, R.C. Reulen, J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, A. Bates, P.M. Stewart, Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J. Clin. Endocrinol. Metab. 94, 1255-1263 (2009)
-
(2009)
J. Clin. Endocrinol. Metab.
, vol.94
, pp. 1255-1263
-
-
Sherlock, M.1
Fernandez-Rodriguez, E.2
Alonso, A.A.3
Reulen, R.C.4
Ayuk, J.5
Clayton, R.N.6
Holder, G.7
Sheppard, M.C.8
Bates, A.9
Stewart, P.M.10
-
29
-
-
0031436037
-
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients
-
M. Muratori, M. Arosio, G. Gambino, C. Romano, O. Biella, G. Faglia, Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. 20, 537-546 (1997)
-
(1997)
J. Endocrinol. Invest.
, vol.20
, pp. 537-546
-
-
Muratori, M.1
Arosio, M.2
Gambino, G.3
Romano, C.4
Biella, O.5
Faglia, G.6
-
30
-
-
77957119638
-
The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment
-
J. Roemmler, B. Steffin, B. Gutt, H.J. Schneider, C. Sievers, M. Bidlingmaier, J. Schopohl, The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm. IGF Res. 20, 338-344 (2010)
-
(2010)
Growth Horm. IGF Res.
, vol.20
, pp. 338-344
-
-
Roemmler, J.1
Steffin, B.2
Gutt, B.3
Schneider, H.J.4
Sievers, C.5
Bidlingmaier, M.6
Schopohl, J.7
-
31
-
-
70449877776
-
ACROSTUDY: The first 5 years
-
P.J. Trainer, ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161(Suppl 1), S19-S24 (2009)
-
(2009)
Eur. J. Endocrinol.
, vol.161
, Issue.SUPPL. 1
-
-
Trainer, P.J.1
-
32
-
-
84859550807
-
Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: A prospective clinical trial
-
C.E. Higham, A.B. Atkinson, S. Aylwin, M. Bidlingmaier, W.M. Drake, A. Lewis, N.M. Martin, V. Moyes, J. Newell-Price, P.J. Trainer, Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J. Clin. Endocrinol. Metab. 97(4), 1187-1193 (2012)
-
(2012)
J. Clin. Endocrinol. Metab.
, vol.97
, Issue.4
, pp. 1187-1193
-
-
Higham, C.E.1
Atkinson, A.B.2
Aylwin, S.3
Bidlingmaier, M.4
Drake, W.M.5
Lewis, A.6
Martin, N.M.7
Moyes, V.8
Newell-Price, J.9
Trainer, P.J.10
-
33
-
-
84873712361
-
Pegvisomant and cabergoline combination therapy in acromegaly
-
I. Bernabeu, C. Alvarez-Escolá, A.E. Paniagua, T. Lucas, I. Pavón, J.M. Cabezas-Agrícola, F.F. Casanueva, M. Marazuela, Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16, 101-108 (2013)
-
(2013)
Pituitary
, vol.16
, pp. 101-108
-
-
Bernabeu, I.1
Alvarez-Escolá, C.2
Paniagua, A.E.3
Lucas, T.4
Pavón, I.5
Cabezas-Agrícola, J.M.6
Casanueva, F.F.7
Marazuela, M.8
-
34
-
-
64549096004
-
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radiotherapy
-
M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N.G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, F.F. Casanueva, I. Bernabeu, Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur. J. Endocrinol. 160, 535-542 (2009)
-
(2009)
Eur. J. Endocrinol.
, vol.160
, pp. 535-542
-
-
Marazuela, M.1
Lucas, T.2
Alvarez-Escola, C.3
Puig-Domingo, M.4
De La Torre, N.G.5
De Miguel-Novoa, P.6
Duran-Hervada, A.7
Manzanares, R.8
Luque-Ramirez, M.9
Halperin, I.10
Casanueva, F.F.11
Bernabeu, I.12
-
35
-
-
33845974147
-
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
-
R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 56, 39-46 (2007)
-
(2007)
N. Engl. J. Med.
, vol.56
, pp. 39-46
-
-
Zanettini, R.1
Antonini, A.2
Gatto, G.3
Gentile, R.4
Tesei, S.5
Pezzoli, G.6
-
36
-
-
84866175011
-
No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly
-
L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714-E1719 (2012)
-
(2012)
J. Clin. Endocrinol. Metab.
, vol.97
-
-
Maione, L.1
Garcia, C.2
Bouchachi, A.3
Kallel, N.4
Maison, P.5
Salenave, S.6
Young, J.7
Assayag, P.8
Chanson, P.9
-
37
-
-
51649119890
-
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
-
M. Kars, V. Delgado, E.R. Holman, R.A. Feelders, J.W. Smit, J.A. Romijn, J.J. Bax, A.M. Pereira, Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348-3356 (2008)
-
(2008)
J. Clin. Endocrinol. Metab.
, vol.93
, pp. 3348-3356
-
-
Kars, M.1
Delgado, V.2
Holman, E.R.3
Feelders, R.A.4
Smit, J.W.5
Romijn, J.A.6
Bax, J.J.7
Pereira, A.M.8
-
38
-
-
67849106650
-
Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas
-
S. Vallette, K. Serri, J. Rivera, P. Santagata, S. Delorme, N. Garfield, N. Kahtani, H. Beauregard, N. Aris-Jilwan, G. Houde, O. Serri, Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12, 153-157 (2009)
-
(2009)
Pituitary
, vol.12
, pp. 153-157
-
-
Vallette, S.1
Serri, K.2
Rivera, J.3
Santagata, P.4
Delorme, S.5
Garfield, N.6
Kahtani, N.7
Beauregard, H.8
Aris-Jilwan, N.9
Houde, G.10
Serri, O.11
-
39
-
-
66149130384
-
Guidelines for acromegaly management: An update
-
Acromegaly Consensus Group
-
S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509-1517 (2009)
-
(2009)
J. Clin. Endocrinol. Metab.
, vol.94
, pp. 1509-1517
-
-
Melmed, S.1
Colao, A.2
Barkan, A.3
Molitch, M.4
Grossman, A.B.5
Kleinberg, D.6
Clemmons, D.7
Chanson, P.8
Laws, E.9
Schlechte, J.10
Vance, M.L.11
Ho, K.12
Giustina, A.13
|